Loading...
Header Logo
Keywords
Last Name
Institution

Christian Mueller PhD

TitleAssociate Professor
InstitutionUniversity of Massachusetts Medical School
DepartmentPediatrics
AddressUniversity of Massachusetts Medical School
368 Plantation Street, AS6-2053
Worcester MA 01605
Phone508-856-4358
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentGene Therapy Center

    InstitutionUMMS - School of Medicine
    DepartmentNeuroNexus Institute

    InstitutionUMMS - School of Medicine
    DepartmentPediatrics
    DivisionPediatric Pulmonology

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentInterdisciplinary Graduate Program

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentMD/PhD Program


    Collapse ORNG Applications 
    Collapse Twitter
    Collapse Websites

    Collapse Biography 
    Collapse education and training
    Florida Institute of Technology, Melbourne, FL, United StatesBSMolecular Biology
    University of Florida, Gainesville, FL, United StatesPHDGenetics

    Collapse Overview 
    Collapse Rotation Projects

    We seek two talented and motivated postdocs to join the laboratory of Dr Christian Mueller in the Horae Gene Therapy Center at the University of Massachusetts Medical School. Our dynamic and collaborative research environment at UMMS includes world renowned clinicians and scientists. Additionally, our location close to Boston supports many collaborations with academic and industrial research groups. Under the leadership of Dr GuangPing Gao, the UMMS GTC is one of the top US gene therapy centers, focusing its research efforts on rare diseases of the liver, CNS, and eye, with a state-of-the-art vector core that handles vector production for its researchers.


     


    Open positions



    1. CNS Lead. Responsible for advancing the lab’s preclinical programs for CNS diseases. Lead indications are SOD1, C9orf72-linked amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD). Projects will include early stage research on genome editing for ALS, an IND-enabling study in non-human primates for a gene therapy candidate for ALS, and an IND-enabling study in non-human primates for a gene therapy candidate for HD.

    2. Liver Lead. Responsible for advancing the lab’s preclinical programs for liver diseases. Lead indication is α-1 antitrypsin deficiency (AATD). Projects will include early research on genome editing for AATD, miRNA roles in liver disease, characterization of two novel animal models for AATD and an IND-enabling study in non-human primates for a gene therapy candidate for AATD.


     


    Applicants should have a PhD in biomedical sciences with a strong background in molecular biology and biochemistry, as well a track record in the field of ALS/CNS disorders (CNS Lead role) or liver diseases (Liver Lead role). Hands-on experience with relevant mouse models as well as excellent knowledge of CRISPR-based genome editing are required. Ability to work independently in a fast-paced research environment and multitask, be highly organized and adaptable are required. Strong writing, verbal and interpersonal skills are required.


     


    Required skills



    • PhD degree in biomedical sciences

    • track record in ALS/CNS disorders or liver diseases with at least two first author publications

    • hands-on experience with genetic mouse models (CNS or liver)

    • excellent knowledge of CRISPR-based gene editing

    • fluently speak and write English


     


    Preferred skills



    • hands-on experience with CRISPR-based gene editing

    • experience in next generation sequencing and bioinformatics

    • experience in tissue culture, cytokine multiplex assays and ELISA


     


    Our lab is multicultural and supports personal development and work-life balance. Attractive salary and benefits available based upon relative working experience.


    Worcester is located an hour away from Boston and offers a good quality of life with plenty or nearby outdoor activities and many restaurants.


    For more information on the Mueller Lab for Gene Therapy we invite you to visit our website: www.umassmed.edu/muellerlab


     



    Currently the lab has rotation projects open on all areas of research. Please visit or lab website (www.umassmed.edu/muellerlab) to what area interests you. 



    Collapse Post Docs

    We seek two talented and motivated postdocs to join the laboratory of Dr Christian Mueller in the Horae Gene Therapy Center at the University of Massachusetts Medical School. Our dynamic and collaborative research environment at UMMS includes world renowned clinicians and scientists. Additionally, our location close to Boston supports many collaborations with academic and industrial research groups. Under the leadership of Dr GuangPing Gao, the UMMS GTC is one of the top US gene therapy centers, focusing its research efforts on rare diseases of the liver, CNS, and eye, with a state-of-the-art vector core that handles vector production for its researchers.


     


    Open positions



    1. CNS Lead. Responsible for advancing the lab’s preclinical programs for CNS diseases. Lead indications are SOD1, C9orf72-linked amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD). Projects will include early stage research on genome editing for ALS, an IND-enabling study in non-human primates for a gene therapy candidate for ALS, and an IND-enabling study in non-human primates for a gene therapy candidate for HD.

    2. Liver Lead. Responsible for advancing the lab’s preclinical programs for liver diseases. Lead indication is α-1 antitrypsin deficiency (AATD). Projects will include early research on genome editing for AATD, miRNA roles in liver disease, characterization of two novel animal models for AATD and an IND-enabling study in non-human primates for a gene therapy candidate for AATD.


     


    Applicants should have a PhD in biomedical sciences with a strong background in molecular biology and biochemistry, as well a track record in the field of ALS/CNS disorders (CNS Lead role) or liver diseases (Liver Lead role). Hands-on experience with relevant mouse models as well as excellent knowledge of CRISPR-based genome editing are required. Ability to work independently in a fast-paced research environment and multitask, be highly organized and adaptable are required. Strong writing, verbal and interpersonal skills are required.


     


    Required skills



    • PhD degree in biomedical sciences

    • track record in ALS/CNS disorders or liver diseases with at least two first author publications

    • hands-on experience with genetic mouse models (CNS or liver)

    • excellent knowledge of CRISPR-based gene editing

    • fluently speak and write English


     


    Preferred skills



    • hands-on experience with CRISPR-based gene editing

    • experience in next generation sequencing and bioinformatics

    • experience in tissue culture, cytokine multiplex assays and ELISA


     


    Our lab is multicultural and supports personal development and work-life balance. Attractive salary and benefits available based upon relative working experience.


    Worcester is located an hour away from Boston and offers a good quality of life with plenty or nearby outdoor activities and many restaurants.


    For more information on the Mueller Lab for Gene Therapy we invite you to visit our website: www.umassmed.edu/muellerlab


     




    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Iyer S, Suresh S, Guo D, Daman K, Chen JCJ, Liu P, Zieger M, Luk K, Roscoe BP, Mueller C, King OD, Emerson CP, Wolfe SA. Precise therapeutic gene correction by a simple nuclease-induced double-stranded break. Nature. 2019 Apr 03. PMID: 30944467.
      View in: PubMed
    2. Gruntman AM, Gernoux G, Tang Q, Ye GJ, Knop DR, Wang G, Benson J, Coleman KE, Keeler AM, Mueller C, Chicoine LG, Chulay JD, Flotte TR. Bridging from Intramuscular to Limb Perfusion Delivery of rAAV: Optimization in a Non-human Primate Study. Mol Ther Methods Clin Dev. 2019 Jun 14; 13:233-242. PMID: 30828586.
      View in: PubMed
    3. Borel F, Mueller C. Design of AAV Vectors for Delivery of RNAi. Methods Mol Biol. 2019; 1950:3-18. PMID: 30783965.
      View in: PubMed
    4. Borel F, Adams E, Mueller C. Intrathecal Delivery of AAV Vectors in Cynomolgus Macaques for CNS Gene Therapy and Gene Expression Analysis in Microdissected Motor Neurons. Methods Mol Biol. 2019; 1937:295-303. PMID: 30706405.
      View in: PubMed
    5. Brehm MA, Kenney LL, Wiles MV, Low BE, Tisch RM, Burzenski L, Mueller C, Greiner DL, Shultz LD. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J. 2018 Nov 01; fj201800636R. PMID: 30383447.
      View in: PubMed
    6. Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH, Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018 Oct 31; 10(465). PMID: 30381409.
      View in: PubMed
    7. Mondo E, Moser R, Gao G, Mueller C, Sena-Esteves M, Sapp E, Pfister E, O'Connell D, Takle K, Erger KE, Liu W, Conlon TJ, DiFiglia M, Gounis MJ, Aronin N. Selective Neuronal Uptake and Distribution of AAVrh8, AAV9, and AAVrh10 in Sheep After Intra-Striatal Administration. J Huntingtons Dis. 2018 Sep 29. PMID: 30320596.
      View in: PubMed
    8. Song CQ, Wang D, Jiang T, O'Connor K, Tang Q, Cai L, Li X, Weng Z, Yin H, Gao G, Mueller C, Flotte TR, Xue W. In vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum Gene Ther. 2018 May 14. PMID: 29597895.
      View in: PubMed
    9. Pfister EL, DiNardo N, Mondo E, Borel F, Conroy F, Fraser C, Gernoux G, Han X, Hu D, Johnson E, Kennington L, Liu P, Reid SJ, Sapp E, Vodicka P, Kuchel T, Morton AJ, Howland D, Moser R, Sena-Esteves M, Gao G, Mueller C, DiFiglia M, Aronin N. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease. Hum Gene Ther. 2018 Jun; 29(6):663-673. PMID: 29207890.
      View in: PubMed
    10. Borel F, Sun H, Zieger M, Cox A, Cardozo B, Li W, Oliveira G, Davis A, Gruntman A, Flotte TR, Brodsky MH, Hoffman AM, Elmallah MK, Mueller C. Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema. Proc Natl Acad Sci U S A. 2018 Mar 13; 115(11):2788-2793. PMID: 29453277.
      View in: PubMed
    11. Durost PA, Aryee KE, Manzoor F, Tisch RM, Mueller C, Jurczyk A, Shultz LD, Brehm MA. Gene Therapy with an Adeno-Associated Viral Vector Expressing Human Interleukin-2 Alters Immune System Homeostasis in Humanized Mice. Hum Gene Ther. 2018 Mar; 29(3):352-365. PMID: 28826231.
      View in: PubMed
    12. Borel F, Tang Q, Gernoux G, Greer C, Wang Z, Barzel A, Kay MA, Shultz LD, Greiner DL, Flotte TR, Brehm MA, Mueller C. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of a-1 Antitrypsin Deficiency. Mol Ther. 2017 Nov 01; 25(11):2477-2489. PMID: 29032169.
      View in: PubMed
    13. Gombash SE, Cowley CJ, Fitzgerald JA, Lepak CA, Neides MG, Hook K, Todd LJ, Wang GD, Mueller C, Kaspar BK, Bielefeld EC, Fischer AJ, Wood JD, Foust KD. Systemic gene delivery transduces the enteric nervous system of guinea pigs and cynomolgus macaques. Gene Ther. 2017 10; 24(10):640-648. PMID: 28771235.
      View in: PubMed
    14. Esanov R, Cabrera GT, Andrade NS, Gendron TF, Brown RH, Benatar M, Wahlestedt C, Mueller C, Zeier Z. A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD. Mol Neurodegener. 2017 Jun 12; 12(1):46. PMID: 28606110.
      View in: PubMed
    15. Pfister EL, Chase KO, Sun H, Kennington LA, Conroy F, Johnson E, Miller R, Borel F, Aronin N, Mueller C. Safe and Efficient Silencing with a Pol II, but Not a Pol lII, Promoter Expressing an Artificial miRNA Targeting Human Huntingtin. Mol Ther Nucleic Acids. 2017 Jun 16; 7:324-334. PMID: 28624208.
      View in: PubMed
    16. Mueller C, Gernoux G, Gruntman AM, Borel F, Reeves EP, Calcedo R, Rouhani FN, Yachnis A, Humphries M, Campbell-Thompson M, Messina L, Chulay JD, Trapnell B, Wilson JM, McElvaney NG, Flotte TR. 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. Mol Ther. 2017 Apr 10. PMID: 28408179.
      View in: PubMed
    17. Gernoux G, Wilson JM, Mueller C. Regulatory and Exhausted T Cell Responses to AAV Capsid. Hum Gene Ther. 2017 Apr; 28(4):338-349. PMID: 28323492.
      View in: PubMed
    18. Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, Mueller C, Flotte TR, Wilson JM. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for a-1-antitrypsin deficiency. Proc Natl Acad Sci U S A. 2017 Feb 14; 114(7):1655-1659. PMID: 28137880.
      View in: PubMed
    19. Guerra ES, Lee CK, Specht CA, Yadav B, Huang H, Akalin A, Huh JR, Mueller C, Levitz SM. Central Role of IL-23 and IL-17 Producing Eosinophils as Immunomodulatory Effector Cells in Acute Pulmonary Aspergillosis and Allergic Asthma. PLoS Pathog. 2017 Jan 17; 13(1):e1006175. PMID: 28095479.
      View in: PubMed
    20. Borel F, Tang Q, Mueller C. Quantification of Z-AAT by a Z-Specific "Sandwich" ELISA. Methods Mol Biol. 2017; 1639:223-226. PMID: 28752462.
      View in: PubMed
    21. Cox A, Mueller C. Quantification of Murine AAT by Direct ELISA. Methods Mol Biol. 2017; 1639:217-222. PMID: 28752461.
      View in: PubMed
    22. Borel F, Mueller C. Design, Cloning, and In Vitro Screening of Artificial miRNAs to Silence Alpha-1 Antitrypsin. Methods Mol Biol. 2017; 1639:107-114. PMID: 28752450.
      View in: PubMed
    23. Liqun Wang R, McLaughlin T, Cossette T, Tang Q, Foust K, Campbell-Thompson M, Martino A, Cruz P, Loiler S, Mueller C, Flotte TR. Recombinant AAV Serotype and Capsid Mutant Comparison for Pulmonary Gene Transfer of a-1-Antitrypsin Using Invasive and Noninvasive Delivery. Mol Ther. 2009 Jan; 17(1):81-87. PMID: 28188992.
      View in: PubMed
    24. Gruenert AK, Czugala M, Mueller C, Schmeer M, Schleef M, Kruse FE, Fuchsluger TA. Self-Complementary Adeno-Associated Virus Vectors Improve Transduction Efficiency of Corneal Endothelial Cells. PLoS One. 2016; 11(3):e0152589. PMID: 27023329; PMCID: PMC4811580.
    25. Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C, Brown RH, Sena-Esteves M. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016 Apr; 79(4):687-700. PMID: 26891182.
      View in: PubMed
    26. Borel F, Gernoux G, Cardozo B, Metterville JP, Toro Cabreja GC, Song L, Su Q, Gao GP, Elmallah MK, Brown RH, Mueller C. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Hum Gene Ther. 2016 Jan; 27(1):19-31. PMID: 26710998.
      View in: PubMed
    27. Liu W, Pfister EL, Kennington LA, Chase KO, Mueller C, DiFiglia M, Aronin N. Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon? J Huntingtons Dis. 2016; 5(1):33-8. PMID: 27003665.
      View in: PubMed
    28. Toro Cabrera G, Mueller C. Design of shRNA and miRNA for Delivery to the CNS. Methods Mol Biol. 2016; 1382:67-80. PMID: 26611579.
      View in: PubMed
    29. Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J, Weiss A, Wightman N, Salameh J, Kim J, Sun H, Boylan KB, Dickson D, Kennedy Z, Lin Z, Zhang YJ, Daughrity L, Jung C, Gao FB, Sapp PC, Horvitz HR, Bosco DA, Brown SP, de Jong P, Petrucelli L, Mueller C, Brown RH. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron. 2015 Dec 02; 88(5):902-9. PMID: 26637797.
      View in: PubMed
    30. Li S, Ling C, Zhong L, Li M, Su Q, He R, Tang Q, Greiner DL, Shultz LD, Brehm MA, Flotte TR, Mueller C, Srivastava A, Gao G. Efficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors. Mol Ther. 2015 Dec; 23(12):1867-76. PMID: 26403887.
      View in: PubMed
    31. Gruntman AM, Su L, Su Q, Gao G, Mueller C, Flotte TR. Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials. Hum Gene Ther Methods. 2015 Apr; 26(2):71-6. PMID: 25819833.
      View in: PubMed
    32. Benskey MJ, Kuhn NC, Galligan JJ, Garcia J, Boye SE, Hauswirth WW, Mueller C, Boye SL, Manfredsson FP. Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants. Mol Ther. 2015 Mar; 23(3):488-500. PMID: 25592336; PMCID: PMC4351472.
    33. Gombash SE, Cowley CJ, Fitzgerald JA, Hall JC, Mueller C, Christofi FL, Foust KD. Intravenous AAV9 efficiently transduces myenteric neurons in neonate and juvenile mice. Front Mol Neurosci. 2014; 7:81. PMID: 25360081; PMCID: PMC4197761.
    34. Flotte TR, Mueller C. What is suppression of anti-adeno-associated virus capsid T-cells achieving? Hum Gene Ther. 2014 Mar; 25(3):178-9. PMID: 24628440.
      View in: PubMed
    35. Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. 2014 Apr; 22(4):692-701. PMID: 24352214; PMCID: PMC3982504.
    36. Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest. 2013 Dec; 123(12):5310-8. PMID: 24231351.
      View in: PubMed
    37. Mueller C, Flotte TR. Gene-based therapy for alpha-1 antitrypsin deficiency. COPD. 2013 Mar; 10 Suppl 1:44-9. PMID: 23527792.
      View in: PubMed
    38. van der Bom IM, Moser RP, Gao G, Mondo E, O'Connell D, Gounis MJ, McGowan S, Chaurette J, Bishop N, Sena-Esteves MS, Mueller C, Aronin N. Finding the striatum in sheep: use of a multi-modal guided approach for convection enhanced delivery. J Huntingtons Dis. 2013; 2(1):41-5. PMID: 25063428.
      View in: PubMed
    39. Gruntman AM, Bish LT, Mueller C, Sweeney HL, Flotte TR, Gao G. Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol. 2013; Chapter 14:Unit 14D.3. PMID: 23408131.
      View in: PubMed
    40. Bickford JS, Mueller C, Newsom KJ, Barilovits SJ, Beachy DE, Herlihy JD, Keeler B, Flotte TR, Nick HS. Effect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency. J Cyst Fibros. 2013 May; 12(3):258-65. PMID: 22985691.
      View in: PubMed
    41. Mueller C, Ratner D, Zhong L, Esteves-Sena M, Gao G. Production and discovery of novel recombinant adeno-associated viral vectors. Curr Protoc Microbiol. 2012 Aug; Chapter 14:Unit14D.1. PMID: 22875565.
      View in: PubMed
    42. Gruntman AM, Mueller C, Flotte TR, Gao G. Gene transfer in the lung using recombinant adeno-associated virus. Curr Protoc Microbiol. 2012 Aug; Chapter 14:Unit14D.2. PMID: 22875566.
      View in: PubMed
    43. Lockett AD, Van Demark M, Gu Y, Schweitzer KS, Sigua N, Kamocki K, Fijalkowska I, Garrison J, Fisher AJ, Serban K, Wise RA, Flotte TR, Mueller C, Presson RG, Petrache HI, Tuder RM, Petrache I. Effect of cigarette smoke exposure and structural modifications on the a-1 Antitrypsin interaction with caspases. Mol Med. 2012 May 09; 18:445-54. PMID: 22245800.
      View in: PubMed
    44. Ratner D, Mueller C. Immune responses in cystic fibrosis: are they intrinsically defective? Am J Respir Cell Mol Biol. 2012 Jun; 46(6):715-22. PMID: 22403802.
      View in: PubMed
    45. Keeler AM, Conlon T, Walter G, Zeng H, Shaffer SA, Dungtao F, Erger K, Cossette T, Tang Q, Mueller C, Flotte TR. Long-term correction of very long-chain acyl-coA dehydrogenase deficiency in mice using AAV9 gene therapy. Mol Ther. 2012 Jun; 20(6):1131-8. PMID: 22395529.
      View in: PubMed
    46. Bickford JS, Newsom KJ, Herlihy JD, Mueller C, Keeler B, Qiu X, Walters JN, Su N, Wallet SM, Flotte TR, Nick HS. Induction of group IVC phospholipase A2 in allergic asthma: transcriptional regulation by TNFa in bronchoepithelial cells. Biochem J. 2012 Feb 15; 442(1):127-37. PMID: 22082005.
      View in: PubMed
    47. Mueller C, Tang Q, Gruntman A, Blomenkamp K, Teckman J, Song L, Zamore PD, Flotte TR. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther. 2012 Mar; 20(3):590-600. PMID: 22252449.
      View in: PubMed
    48. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, Campbell-Thompson M, Yachnis AT, Sandhaus RA, McElvaney NG, Mueller C, Messina LM, Wilson JM, Brantly M, Knop DR, Ye GJ, Chulay JD. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing a1-antitrypsin: interim results. Hum Gene Ther. 2011 Oct; 22(10):1239-47. PMID: 21609134.
      View in: PubMed
    49. Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R, Xu Z, Gao G. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther. 2011 Aug; 19(8):1440-8. PMID: 21610699.
      View in: PubMed
    50. Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K, Catalano D, Mandrekar P, Szabo G. Hepatocyte-specific hypoxia-inducible factor-1a is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology. 2011 May; 53(5):1526-37. PMID: 21520168.
      View in: PubMed
    51. Flotte TR, Frederickson RM, Lowenstein PR, Mueller C. Moving forward toward a cure for Parkinson's: neuropathology of the nigrostriatal pathway determines the location of growth factor delivery. Mol Ther. 2011 May; 19(5):827-9. PMID: 21532611.
      View in: PubMed
    52. Flotte TR, Mueller C. Gene therapy for alpha-1 antitrypsin deficiency. Hum Mol Genet. 2011 Apr 15; 20(R1):R87-92. PMID: 21498872.
      View in: PubMed
    53. Flotte TR, Conlon TJ, Mueller C. Preclinical study design for rAAV. Methods Mol Biol. 2011; 807:317-37. PMID: 22034037.
      View in: PubMed
    54. Xie J, Xie Q, Zhang H, Ameres SL, Hung JH, Su Q, He R, Mu X, Seher Ahmed S, Park S, Kato H, Li C, Mueller C, Mello CC, Weng Z, Flotte TR, Zamore PD, Gao G. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther. 2011 Mar; 19(3):526-35. PMID: 21179009.
      View in: PubMed
    55. Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol. 2011 Jun; 44(6):922-9. PMID: 20724552.
      View in: PubMed
    56. Martino AT, Mueller C, Braag S, Cruz PE, Campbell-Thompson M, Jin S, Flotte TR. N-glycosylation augmentation of the cystic fibrosis epithelium improves Pseudomonas aeruginosa clearance. Am J Respir Cell Mol Biol. 2011 Jun; 44(6):824-30. PMID: 20693405.
      View in: PubMed
    57. Harrison LH, Tam SK, Mueller CP. Partial anomalous pulmonary venous connection in adults: a simplified approach. Ann Thorac Surg. 2010 Jan; 89(1):283-5. PMID: 20103258.
      View in: PubMed
    58. Mueller C, Keeler A, Braag S, Menz T, Tang Q, Flotte TR. Modulation of exaggerated-IgE allergic responses by gene transfer-mediated antagonism of IL-13 and IL-17e. Mol Ther. 2010 Mar; 18(3):511-8. PMID: 19935781.
      View in: PubMed
    59. Mueller C, Strayer MS, Sirninger J, Braag S, Branco F, Louboutin JP, Flotte TR, Strayer DS. In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors. Gene Ther. 2010 Feb; 17(2):227-37. PMID: 19890354.
      View in: PubMed
    60. Flotte TR, Fischer AC, Goetzmann J, Mueller C, Cebotaru L, Yan Z, Wang L, Wilson JM, Guggino WB, Engelhardt JF. Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther. 2010 Mar; 18(3):594-600. PMID: 19826405.
      View in: PubMed
    61. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR, Spencer C, Byrne BJ, Wilson JM, Flotte TR. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A. 2009 Sep 22; 106(38):16363-8. PMID: 19706466.
      View in: PubMed
    62. Mueller C, Flotte TR. Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol. 2008 Dec; 35(3):164-78. PMID: 18600482.
      View in: PubMed
    63. Liqun Wang R, McLaughlin T, Cossette T, Tang Q, Foust K, Campbell-Thompson M, Martino A, Cruz P, Loiler S, Mueller C, Flotte TR. Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol Ther. 2009 Jan; 17(1):81-7. PMID: 18941444.
      View in: PubMed
    64. Mueller C, Braag SA, Martino AT, Tang Q, Campbell-Thompson M, Flotte TR. The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/- -dependent allergy mouse model. Gene Ther. 2009 Feb; 16(2):172-83. PMID: 18818669.
      View in: PubMed
    65. Stalvey MS, Brusko TM, Mueller C, Wasserfall CH, Schatz DA, Atkinson MA, Flotte TR. CFTR mutations impart elevated immune reactivity in a murine model of cystic fibrosis related diabetes. Cytokine. 2008 Oct; 44(1):154-9. PMID: 18778952.
      View in: PubMed
    66. Flotte TR, Goetzmann J, Caridi J, Paolillo J, Conlon TJ, Potter M, Mueller C, Byrne BJ. Apparently nonspecific enzyme elevations after portal vein delivery of recombinant adeno-associated virus serotype 2 vector in hepatitis C virus-infected chimpanzees. Hum Gene Ther. 2008 Jul; 19(7):681-9. PMID: 18588426.
      View in: PubMed
    67. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008 Jun; 15(11):858-63. PMID: 18418415.
      View in: PubMed
    68. Mueller C, Torrez D, Braag S, Martino A, Clarke T, Campbell-Thompson M, Flotte TR. Partial correction of the CFTR-dependent ABPA mouse model with recombinant adeno-associated virus gene transfer of truncated CFTR gene. J Gene Med. 2008 Jan; 10(1):51-60. PMID: 18023072.
      View in: PubMed
    69. Cruz PE, Mueller C, Flotte TR. The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency. Pharmacogenomics. 2007 Sep; 8(9):1191-8. PMID: 17924834.
      View in: PubMed
    70. Cruz PE, Mueller C, Cossette TL, Golant A, Tang Q, Beattie SG, Brantly M, Campbell-Thompson M, Blomenkamp KS, Teckman JH, Flotte TR. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest. 2007 Sep; 87(9):893-902. PMID: 17592477.
      View in: PubMed
    71. Müller C, Braag SA, Herlihy JD, Wasserfall CH, Chesrown SE, Nick HS, Atkinson MA, Flotte TR. Enhanced IgE allergic response to Aspergillus fumigatus in CFTR-/- mice. Lab Invest. 2006 Feb; 86(2):130-40. PMID: 16424881.
      View in: PubMed
    72. Virella-Lowell I, Herlihy JD, Liu B, Lopez C, Cruz P, Muller C, Baker HV, Flotte TR. Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line. Mol Ther. 2004 Sep; 10(3):562-73. PMID: 15336656.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Mueller's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _